Group 1 - The new tax policy allows companies to fully deduct expenses for software, equipment, and R&D in the year they are incurred, improving cash flow for businesses [3][5] - The U.S. government aims to stimulate domestic investment through this policy, but it may lead to significant long-term fiscal deficits, with an estimated $3.63 trillion in tax revenue loss over the next decade [5] - Many U.S. companies, such as Lumen and AT&T, are adjusting their investment plans to take advantage of the tax benefits, with Lumen's CFO highlighting its critical importance for data center investments [7][9] Group 2 - Multinational corporations, like AstraZeneca and Heineken, view the U.S. tax policy as having limited impact on their core strategies, focusing instead on product demand and regulatory policies [12][16] - AstraZeneca continues its $500 billion investment plan in the U.S. despite the new tax policy, indicating that their strategic decisions were made prior to the policy's introduction [14] - Heineken's CFO emphasizes the long-term nature of brewery investments and the need for market stability over short-term tax incentives, as the company faces declining sales in key markets [18][22] Group 3 - The AI sector, represented by OpenAI, acknowledges the tax benefits for R&D but stresses that the industry's growth relies more on technology application and market demand than on tax incentives [29] - The "Big and Beautiful Act" reflects varying strategic choices among companies, with domestic firms seizing short-term benefits while multinationals maintain their long-term strategies [31] - Companies must focus on their core competencies and market needs for sustainable growth, as reliance on policy benefits is only a temporary solution [33]